Botanical Interventions to Improve Glucose Control and Options for Diabetes Therapy

Peter Smoak1, Susan J Burke2, J Jason Collier1

  • 1Laboratory of Islet Biology and Inflammation, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.

Insights

This review explores plant-derived compounds for diabetes treatment. Herbal extracts and phytochemicals show potential for managing type 1 (T1DM) and type 2 diabetes (T2DM) by improving pancreatic beta-cell function and mass.

Area of Science:

  • Endocrinology and Metabolic Diseases
  • Pharmacognosy
  • Natural Product Chemistry

Background:

  • Diabetes mellitus, a global health crisis, presents as type 1 (autoimmune) and type 2 (obesity-related).
  • Both diabetes types are characterized by impaired pancreatic islet beta-cell function and reduced cell mass.
  • Traditional use of diverse plant species offers a historical precedent for exploring botanical agents in diabetes management.

Purpose of the Study:

  • To systematically review phytochemicals and herbal extracts investigated for anti-diabetic properties.
  • To evaluate the therapeutic potential of botanical agents in preclinical and clinical settings.
  • To identify botanical formulations as candidates for future diabetes drug discovery.

Main Methods:

  • Literature review of studies examining crude plant extracts and purified compounds.
  • Analysis of preclinical (in vitro, animal models) and clinical trial data.
  • Comparison of botanical treatments with standard-of-care diabetes medications.

Main Results:

  • Numerous phytochemicals and herbal extracts have demonstrated anti-diabetic effects in various study designs.
  • Evidence suggests potential benefits for both pancreatic beta-cell function and mass.
  • Some botanical agents have shown comparable or complementary effects to conventional therapies.

Conclusions:

  • Botanical formulations represent a promising area for the development of novel anti-diabetic therapeutics.
  • Further research and refinement of plant-derived compounds could lead to new treatments or adjunct therapies for diabetes.
  • Phytochemicals hold potential for direct therapeutic benefit or as adjuvant therapy in diabetes management.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
428
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
305
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
279
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
366
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.4K